Hepoxilin analogs, PBT-3 and PBT-4, cause apoptosis of Gleevec-resistant K562 cells in vitro

In Vivo

Volumn 21, Issue 2, 2007, Pages 267-271

  Qiao, Na ^a   Reynaud, Denis ^a   Abdelhaleem, Mohamed ^a   Pace Asciak, Cecil R ^a,b  

^a HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

Apoptosis; Gleevec resistance; Hepoxilin analog; K562 cells; Leukemia; PBT 3; PBT 4

Indexed keywords

BCR ABL PROTEIN; CYTOCHROME C; DIMETHYL SULFOXIDE; HEPOXILIN B; IMATINIB; PROTEIN TYROSINE KINASE;

APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL STRAIN; CELL SURVIVAL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; GROWTH INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL;

EID: 34047203461     PISSN: 0258851X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Weisberg E and Griffin JD: Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95: 3498-3505, 2000.
2. Hariharan IK, Harris AW, Crawford M, Abud H, Webb E, Cory S and Adams JM: A bcr-v-abl oncogene induces lymphomas in transgenic mice. Mol Cell Biol 9: 2798-2805, 1989.
3. Mahon FX, Deininger MW, Schultheis B, Chabrol J, Reiffers J, Goldman JM and Melo JV: Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor ST1571: diverse mechanisms of resistance. Blood 96: 1070-1079, 2000.
4. Dou QP, Mcguire TF, Peng Y and An B: Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cells. J Pharmacol Exp Ther 289: 781-790, 1999.
5. Urbano A, Koc Y and Foss FM: Arginine butyrate downregulates p210 bcr-abl expression and induces apoptosis in chronic myelogenous leukemia cells. Leukemia 12: 930-936, 1998.
6. Deora AB, Miranda MB and Rao SG: Down-modulation of P210 bcr/abl induces apoptosis/differentiation in K562 leukemic blast cells. Tumori 83: 756-761, 1997.
7. Gambacorti-Passerini C, Le Coutre P, Mologni L, Fanelli M, Bertazzoli C, Marchesi E, Di Nicola M, Biondi A, Corneo, GM Belotti D, Pogliani E and Lydon NB: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23: 380-394, 1997.
8. Capdeville R, Buchdunger E, Zimmermann J and Matter A: Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug. Nat Rev Drug Discov 1: 493-502, 2002.
9. Druker BJ: Perspectives on the development of a molecularly targeted agent. Cancer Cell 1: 31-36, 2002.
10. Amarante-Mendes GP, Kim CN, Liu L, Huang U, Perkins C, Green DR and Bhalla K: Bcr-Abl exerts its antiapoptotic effect against diverse apoptotic stimuli through blockage of mitochondrial release of cytochrome c and activation of caspase-3. Blood 91: 1700-1705, 1998.
11. Pace-Asciak CR and Martin JM: Hepoxilin, a new family of insulin secretagogues formed by intact rat pancreatic islets. Prostagl. Leukotriene and Med 16: 173-180, 1984.
12. Demin PM and Pace-Asciak CR: Synthesis of racemic 11,12-cyclopropyl analogs of hepoxilins A3 and B3. Tetrahedron Lett 34: 4305-4308, 1993.
13. Qiao N, Lam J, Reynaud D, Abdelhaleem M and Pace-Asciak CR: The hepoxilin analog PBT-3 induces apoptosis in BCR-ABL-positive K562 leukemia cells. Anticancer Res 23: 3617-3622, 2003.
14. Li X, Qiao N, Reynaud D, Abdelhaleem M and Pace-Asciak CR: The hepoxilin analog, PBT-3, inhibits growth of K-562 CML solid tumours in vivo in nude mice. In Vivo 19: 185-190, 2005.
15. Yu C, Krystal G, Varticovski L, Mckinstry R, Rahmani M, Dent P and Grant S: Pharmacologic mitogen-activated protein/extracellular signal-regulated kinase kinase/mitogen-activated protein kinase inhibitors interact synergistically with ST1571 to induce apoptosis in Bcr/Abl-expressing human leukemia cells. Cancer Res 62: 188-199, 2002.
16. Le Coutre P, Tassi E, Varella-Garcia M, Barni R, Mologni L, Cabrita G, Marchesi E, Supino R and Gambacorti-Passerini C: Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification. Blood 95: 1758-1766, 2000.
17. Li J, Patwari Y, Kelsey S and Newland A: TRAIL-induced apoptosis in type I leukemic cells is not enhanced by overexpression of Bax. Biochem Biophys Res Commun 283: 1037-1045, 2001.
18. Pace-Asciak CR, Reynaud D, Demin P, Aslam R and Sun A: A new family of thromboxane receptor antagonists with secondary thromboxane synthase inhibition. J Pharmacol Exper Ther 301: 618-624, 2002.
19. Jankov RP, Luo X, Demin P, Aslam R, Hannam V, Tanswell AK and Pace-Asciak CR: Hepoxilin analogs inhibit bleomycin-induced pulmonary fibrosis in the mouse. J Pharm Exp Ther 301: 435-440, 2002.
20. Pace-Asciak CR, Li X, Qiao N, Reynaud D, Demin P and Abdelhaleem M: Hepoxilin analogs, potential new therapeutics in disease. Current Pharmaceutical Design 12: 963-969, 2006.